An Observational Extension Study for Adult Patients Treated in Study R5459-RT-1944 Who Receive a Kidney Transplant
← catalyst calendarNCT05106387 · readout in 299 d
Sponsored by Regeneron Pharmaceuticals (industry) · REGN — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
20estimated
Sites
9
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2023-10-19 | actual | When the study began enrolling |
| Primary completion | 2027-06-14 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-02-23 | estimated | The whole study's end, after follow-up |
| First posted | 2021-11-03 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-20 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Chronic Kidney Disease (CKD)
Intervention
- Drug: Noninterventional — also filed as REGN5459
Primary outcomes
what the primary-completion date above is the date OFIncidence of Adverse Events
measured Up to 12 months post-kidney transplant
Incidence of Serious Adverse Events
measured Up to 12 months post-kidney transplant
Permalink · REGN's whole pipeline · Catalyst calendar · Every registered study · What changed